Recent Finacing
Recent Raise
NeuCyte develops the SynFire platform using iPSC-derived neuronal subtypes co-cultured with astroglia to enable human phenotypic and target-based drug screens for Fragile X and other genetic neurological disorders.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at NeuCyte.
